Senior Director
Evidera. Inc., PPD, a part of Thermo Fisher Scientific
Boston, United States
Meredith Smith, PhD, MPA, FISPE is Senior Director and Head of the Implementation Science Group at Evidera, Inc./PPD, a healthcare consultancy within Thermo Fisher Scientific. Dr. Smith is trained as a health services researcher. She has over 20 years of experience in the pharmaceutical industry where she worked in health outcomes, regulatory policy and drug safety and applied implementation science methods and measurements to the design, implementation and evaluation of interventions to support the safe and appropriate use of medicines. Before joining industry, she was on the faculty at Memorial Sloan-Kettering Cancer Center, and at the Mount Sinai School of Medicine, in New York City where she was a Principal Investigator on numerous grant-funded research projects focusing on healthcare system interventions to improve quality of life, adjustment to illness, symptom management, and medication adherence among cancer patients and persons living with HIV/AIDS. Prior to that, Dr. Smith worked at the US Centers for Disease Control and Prevention as part of the team establishing the Behavioral Risk Factor Surveillance System. Dr. Smith received her PhD from the Robert F. Wagner School of Public Service at New York University, her MPA from the New School for Social Research, and a B.A. from Barnard College, Columbia University. She has published extensively in the health sciences literature, been a member of three CIOMS Working Groups, IMI-PREFER, and has been an invited speaker at Food and Drug Administration (FDA) public workshops and internal meetings. She is a Fellow of the International Society for Pharmacoepidemiology (ISPE) and an adjunct associate professor in the department of Regulatory and Quality Sciences at the Alfred E. Mann School of Pharmacy, University of Southern California.
Disclosure information not submitted.
Saturday, August 24, 2024
9:00 AM – 12:30 PM CEST
Tuesday, August 27, 2024
8:00 AM – 8:15 AM CEST
Why Real World Evidence (RWE) Studies Need Implementation Research: The Value Proposition
Tuesday, August 27, 2024
4:15 PM – 5:45 PM CEST
Risk Minimization Programs for Teratogenic Drugs: How to Move from Art to Science
Wednesday, August 28, 2024
10:30 AM – 12:00 PM CEST